Phase 4 N=150 Lifestyle Modification and Liraglutide
Obesity
Primary: Percent Change in Baseline Weight — -6.1; -11.5; -11.8 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=34 Octylseal Surgical Adhesive in General Surgery
Wounds
Primary: Wound Length Closure — 28.97; 21.00 milimeters
Phase 4 N=224 Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease in Children Aged Between 6 and 9 Years — 290.4; 719.2; 381.2; 393.9…
Phase 4 N=37 Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation
Hyperlipidemia
Primary: Flow-mediated Dilation (FMD) With Fasting State at Baseline, Week 4 and Week 8 — 6.71; 5.85; 5.85; 3.15 Percentage of dilation
Phase 4 N=22 Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
Ocular Hypertension · Glaucoma, Open-Angle
Primary: Mean Intraocular Pressure — 14.7; 14.8 mmHg
Phase 4 N=40 Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
Obesity, Visceral
Primary: Change in Glycerol Enrichment — 6.5; 1.4 Percentage change — p=0.0053
Phase 4 N=28 Vildagliptin Versus Dapagliflozin on Glucagon
Type 2 Diabetes
Primary: Glucagon Response to Meal — 39.0; 38.8 nmol/l min
Phase 4 N=30 IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
Diabetic Macular Edema
Primary: Reduction in Macular Edema — 15; 8; 4 Participants
Phase 4 N=3,304 A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)
Diabetes Mellitus, Type 2
Primary: Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without…
Phase 4 N=12 A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h]) — -238.46; 15.56 milligram*hour per deciliter…
Phase 4 N=970 TiLE (Time Lapse Eeva) Clinical Trial
Fertility
Primary: Implantation Rate — 30.1; 35.3 % of sacs per embryo transferred
Phase 4 N=1,053 Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Mean Change From Baseline in Post-dose Trough FEV1 — -0.029; -0.003 Liters — p=0.0404
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
Phase 4 N=142 Dutasteride Treatment for the Reduction of Heavy Drinking in Men
Alcoholism · Alcohol Abuse · Alcohol Dependence
Primary: Heavy Drinking Days Per Week — 1.75; 2.67 heavy drinking days/week — p=0.002
Phase 4 N=129 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Post-Treatment Maximum Eosinophil Count (Aim 1) — 14.7; 20.9 eosinophils per high-power field — p=0.31